Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, significantly reduces HbA1c and body weight in patients with type 2 diabetes and obesity, demonstrating superior efficacy compared to placebo, semaglutide, and basal insulin.
Tirzepatide is a once-weekly injection that activates two gut hormones (GLP-1 and GIP) to lower blood sugar and promote significant weight loss. It is approved for Type 2 Diabetes and Obesity. Clinical trials show it lowers HbA1c more effectively than other common diabetes drugs and leads to greater weight loss than GLP-1-only drugs like semaglutide. Start with a low dose (2.5 mg) and increase slowly to minimize stomach upset. It requires a prescription and lifestyle changes (diet/exercise).
Tirzepatide is a novel dual incretin receptor agonist (twincretin) that activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors... Data from preclinical and clinical trials have shown that twincretins significantly reduce blood glucose levels in T2D... the beneficial impact of tirzepatide on weight reduction has been corroborated in several studies, showing that this agent can achieve substantial and sustained weight loss in obese patients with or without T2D.
Why this rating
The review synthesizes data from multiple Phase 3 randomized controlled trials (SURPASS-1 to 5, SURMOUNT-1) which are high-quality evidence.
Source
Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review
Alexandros L. Liarakos et al. · Biomedicines · 2023
DOI 10.3390/biomedicines11071875
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →